← Leaderboards
David W Oslin
Philadelphia Va Medical Center
$10,174,874
Attributed
$11,954,442
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,954,442 · 7
VA$0 · 3
By mechanism
R01$9,890,741 · 3
K08$717,383 · 1
T32$692,231 · 1
R21$374,062 · 1
P50$280,025 · 1
I01$0 · 2
Top collaborators
- Jyotishman Pathak5 shared
Most similar at Philadelphia Va Medical Center
Same institution · by research overlap
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseInnovationPharmaceutical PreparationsProgramsVeteransMedicalNaltrexoneReportingCostVariantPersonsSiteCaringPharmacogeneticsRandomizedGeneticMortalityTreatment ResponseDesignOutcome MeasureSecondary OutcomeDrinkingAlcohol DependenceHeavy Drinking
Grant awards (49)
Linking VA and non-VA data to study the risk of suicide in chronic pain patients.$669,151
R01 · FY2024 · MH
PRIME Care (PRecision medicine In MEntal health Care)$0
IP1 · FY2024 · VA · contact PI
Linking VA and non-VA data to study the risk of suicide in chronic pain patients.$680,497
R01 · FY2023 · MH
Linking VA and non-VA data to study the risk of suicide in chronic pain patients.$693,707
R01 · FY2022 · MH
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2022 · VA · contact PI
Linking VA and non-VA data to study the risk of suicide in chronic pain patients.$707,472
R01 · FY2021 · MH
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2021 · VA · contact PI
PRIME Care (PRecision medicine In MEntal health Care)$0
IP1 · FY2021 · VA · contact PI
Linking VA and non-VA data to study the risk of suicide in chronic pain patients.$808,310
R01 · FY2020 · MH
PRIME Care (PRecision medicine In MEntal health Care)$0
IP1 · FY2020 · VA · contact PI
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2020 · VA · contact PI
PRIME Care (PRecision medicine In MEntal health Care)$0
IP1 · FY2020 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2019 · VA · contact PI
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2019 · VA · contact PI
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2018 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2018 · VA · contact PI
PRIME Care (PRecision medicine In MEntal health Care)$0
IP1 · FY2018 · VA · contact PI
Topiramate Treatment of Alcohol Use Disorder in African Americans$0
I01 · FY2017 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2017 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2016 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2015 · VA · contact PI
Reducing the Burden of Depression on Employment: Improving function and work$0
I01 · FY2015 · VA · contact PI
Pharmacogenetic Response to Naltrexone for Alcohol Dependence$576,221
R01 · FY2012 · AA · contact PI
Pharmacogenetic Response to Naltrexone for Alcohol Dependence$590,785
R01 · FY2011 · AA · contact PI
Pharmacogenetic Response to Naltrexone for Alcohol Dependence$600,535
R01 · FY2010 · AA · contact PI
NRSA Training: Psychiatric-Medical Comorbidity in Aging$191,462
T32 · FY2010 · MH · contact PI
Pharmacogenetic Response to Naltrexone for Alcohol Dependence$609,120
R01 · FY2009 · AA · contact PI
Defining an endophenotype for opioid dysregulation: A pilot study$187,031
R21 · FY2009 · AA · contact PI
NRSA Training: Psychiatric-Medical Comorbidity in Aging$145,762
T32 · FY2009 · MH · contact PI
Pharmacogenetic Response to Naltrexone for Alcohol Dependence$629,720
R01 · FY2008 · AA · contact PI
Defining an endophenotype for opioid dysregulation: A pilot study$187,031
R21 · FY2008 · AA · contact PI
NRSA Training: Psychiatric-Medical Comorbidity in Aging$159,566
T32 · FY2008 · MH · contact PI
Genetic Contributions to Treatment Response$53,987
P50 · FY2008 · DA · contact PI
Non-response to NTX next steps in managing alcoholism$588,001
R01 · FY2007 · AA · contact PI
NRSA Training: Psychiatric-Medical Comorbidity in Aging$111,293
T32 · FY2007 · MH · contact PI
Genetic Contributions to Treatment Response$70,467
P50 · FY2007 · DA · contact PI
Non-response to NTX next steps in managing alcoholism$666,120
R01 · FY2006 · AA · contact PI
Non-response to NTX next steps in managing alcoholism$136,537
R01 · FY2006 · AA · contact PI
NRSA Training: Psychiatric-Medical Comorbidity in Aging$84,148
T32 · FY2006 · MH · contact PI
Genetic Contributions to Treatment Response$52,828
P50 · FY2006 · DA · contact PI
Non-response to NTX next steps in managing alcoholism$669,781
R01 · FY2005 · AA
Genetic Contributions to Treatment Response$51,980
P50 · FY2005 · DA
Non-response to NTX next steps in managing alcoholism$649,901
R01 · FY2004 · AA
Genetic Contributions to Treatment Response$50,763
P50 · FY2004 · DA
Non-response to NTX next steps in managing alcoholism$614,883
R01 · FY2003 · AA
TREATMENT OF LATE LIFE DEPRESSION COMPLICATED BY ALCOHOL$179,361
K08 · FY2003 · MH
TREATMENT OF LATE LIFE DEPRESSION COMPLICATED BY ALCOHOL$179,322
K08 · FY2002 · MH
TREATMENT OF LATE LIFE DEPRESSION COMPLICATED BY ALCOHOL$179,321
K08 · FY2001 · MH
TREATMENT OF LATE LIFE DEPRESSION COMPLICATED BY ALCOHOL$179,379
K08 · FY2000 · MH